A review recognizing Cerebrolysin® as a cytoprotective and neurogenerative drug treating secondary damage after sTBI
Severe traumatic brain injury (sTBI) is both a personal and socioeconomic disaster, due to high treatment and rehabilitation costs and loss of productivity. Posttraumatic quality of life is often significantly impaired by mobility-limiting motor handicaps and essential cognitive and emotional dysfunctions. Initial traumatic lesions are typically cause secondary damages that trigger further functional impairment.
The review of Trimmel et al. shows the early treatment stages of sTBI, focusing on current pharmacological options for preventing and treating secondary damage.
Cerebrolysin® is recognized as a cytoprotective and neuroregenerative drug for the treatment of severe traumatic brain injury (sTBI).
The review addresses the following:
- Explaining the mechanisms of action of Cerebrolysin® and its effects
- Showing that early clinical improvement in cognitive and emotional outcomes due to Cerebrolysin® treatment
- Highlighting the recognition in the Canadian ERABI guideline, highlighting Cerebrolysin® as a 1b recommendation; improving attentional function in patients with moderate to severe TBI.
- Drawing attention to the fact that Cerebrolysin® is the first guideline recommended neurothropic drug
Given the magnitude of the individual as well as socioeconomic catastrophe that sTBI represents worldwide, the review comes to the conclusion that more efforts should be made to improve the prognosis of the mostly young individuals affected by sTBI.
An adjunctive treatment with the cerebroprotective agent Cerebrolysin® appears to be a sensible option for the treatment of individuals affected by sTBI.
Moreover, Cerebrolysin’s status as a trusted and evidence-based intervention in the treatment of TBI is further underscored by its recent recognition in the internationally highly respected Canadian INCOG guidelines. This endorsement highlights the growing consensus within the medical community regarding the efficacy of Cerebrolysin® in improving outcomes for TBI patients.